Epistaxis Clinical Trial
Official title:
The Roles of Hilotherapy in the Management of Epistaxis and Nasal Fractures
The Investigators aimed to assess primarily whether or not Hilotherapy masks are a tolerable treatment for the conservative management of epistaxis and nasal fractures.
Participants who had ongoing epistaxis and met the inclusion criteria where enrolled in the
pilot study . Bleeding severity was not recorded. All participants enrolled were clinically
stable with active epistaxis. Participants who were unstable or were ineligible were not
referred to the recruiting doctors by A&E triage. Following informed consent the Hilotherm
mask was fitted for an initial period of 20 minutes. If the bleeding had improved or stopped
following 20 minutes of treatment the Hilotherm mask remained fitted for a 20 further minutes
. A subjective decision was made by the supervising doctor and the participant to whether the
flow of epistaxis had improved after the initial 20 minutes of hilotherapy.
The mask was removed if there was no improvement after the initial 20 minutes of hilotherapy,
40 minutes of total hilotherapy treatment, participant preference, worsening observations or
profuse bleeding. Participants received conventional epistaxis management simultaneously,
this involved continued nasal pressure application during hilotherapy. Following hilotherapy
if epistaxis continued then either nasal cauterisation or packing was performed. Participants
who were packed cessation of epistaxis was determined at the time of packing if bleeding had
ceased. Bleeding time was accurately assessed by the recruiting doctor from the time of
hilotherm mask application to the time of complete epistaxis cessation. All of the
participants were treated in the sitting position.
Participants were free to withdraw from the trial at any time and no further data was
analysed from the individual. Clinicians recorded anticoagulant and antiplatelet use,
duration of bleeding and patient demographics. All participants completed a questionnaire
following their hilotherapy treatment independantly.
A similar protocol was devised for nasal fractures.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05334017 -
Xylometazoline and Cocaine for Nasal Vasoconstriction
|
Phase 4 | |
Not yet recruiting |
NCT04519463 -
The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing
|
Early Phase 1 | |
Recruiting |
NCT01886768 -
Double Versus Single Pledget Nasal Anesthesia for Transnasal Endoscopy
|
N/A | |
Recruiting |
NCT00390663 -
A Prospective Randomised Controlled Trial of Management of Recurrent Nosebleeds in Children
|
Phase 4 | |
Suspended |
NCT04054687 -
Intranasal TXA for Anterior Epistaxis in the Emergency Department
|
Phase 2 | |
Completed |
NCT02285634 -
The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.
|
N/A | |
Completed |
NCT01485224 -
Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia
|
Phase 2 | |
Completed |
NCT00793117 -
The Effect of Packing in Post Operative Management of FESS
|
Phase 4 | |
Recruiting |
NCT06259292 -
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
|
||
Recruiting |
NCT03850964 -
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
|
Phase 2/Phase 3 | |
Recruiting |
NCT05281952 -
Medico-economic Evaluation of Management Strategies for Severe Epistaxis
|
N/A | |
Completed |
NCT03360045 -
Comparing Effectiveness of Merocel and Packing With Tranexamic Acid in the Management of Anterior Epistaxis
|
Phase 4 | |
Completed |
NCT03912051 -
Assessment of Performance and Safety of an Asymmetric Balloon in the Treatment of Intranasal Bleeding Managed in an Emergency Setting
|
N/A | |
Not yet recruiting |
NCT02677467 -
Correlation Between Epistaxis and Cardiovascular Disease
|
N/A | |
Completed |
NCT01314274 -
Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 2 | |
Terminated |
NCT01051427 -
Control of Epistaxis With Surgiflo
|
N/A | |
Completed |
NCT00863356 -
Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis
|
N/A | |
Recruiting |
NCT05269849 -
Sirolimus for Nosebleeds in HHT
|
Phase 2 | |
Not yet recruiting |
NCT05343650 -
NOVAPAK Nasal Packing in Shellfish Allergic Patients
|
Phase 4 | |
Not yet recruiting |
NCT02963129 -
Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT
|
Phase 3 |